
2017 OPTIONS FOR INDIVIDUAL MEASURES:
REGISTRY ONLY

MEASURE TYPE:
Process

DESCRIPTION:
Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low (or very low) risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer

INSTRUCTIONS:
This measure is to be reported once per episode of treatment (i.e., interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy) for all male patients with prostate cancer who receive interstitial prostate brachytherapy, external beam radiotherapy to the prostate, radical prostatectomy, or cryotherapy during the performance period. Each episode of radiation therapy in an eligible patient receiving external beam radiotherapy to the prostate occurring during the performance period will be counted when calculating the data completeness and performance rates. The quality-data code or equivalent needs to be submitted only once during the episode of radiation therapy (e.g., 8 weeks of therapy). It is anticipated that eligible clinicians who perform the listed procedures as specified in the denominator coding will submit this measure.

Measure Reporting:
The listed denominator criteria is used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions allowed by the measure. The quality-data codes listed do not need to be submitted for registry-based submissions; however, these codes may be submitted for those registries that utilize claims data.

DENOMINATOR:
All patients, regardless of age, with a diagnosis of prostate cancer at low (or very low) risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy

Definitions:
Risk Strata: Very Low, Low, Intermediate, High, or Very High-
Very Low Risk - PSA < 10 ng/mL; AND Gleason score 6 or less; AND clinical stage T1c; AND presence of disease in fewer than 3 biopsy cores; AND <= 50% prostate cancer involvement in any core; AND PSA density <= 0.15 ng/mL/cm3.
Low Risk - PSA < 10 ng/mL; AND Gleason score 6 or less; AND clinical stage T1 to T2a.
Intermediate Risk - PSA 10 to 20 ng/mL; OR Gleason score 7; OR clinical stage T2b to T2c.
Note: Patients with multiple adverse factors may be shifted into the high risk category.
High Risk - PSA > 20 ng/mL; OR Gleason score 8 to 10; OR clinically localized stage T3a.
Note: Patients with multiple adverse factors may be shifted into the very high risk category.
Very High Risk - Clinical stage T3b to T4; OR primary Gleason pattern 5; OR more than 4 cores with Gleason score 8 to 10. (NCCN, 2016)
External beam radiotherapy – external beam radiotherapy refers to 3D conformal radiation therapy (3D-CRT), intensity modulated radiation therapy (IMRT), stereotactic body radiotherapy (SBRT), and proton beam therapy.
Denominator Criteria (Eligible Cases):
Any male patient, regardless of age
AND
Diagnosis for prostate cancer (ICD-10-CM): C61
AND
Patient encounter during the performance period (CPT): 55810, 55812, 55815, 55840, 55842, 55845, 55866, 55873, 55875, 77427, 77435, 77772, 77778, 77799
AND
Low (or very low) risk of recurrence, prostate cancer: G9706

NUMERATOR:
Patients who did not have a bone scan performed at any time since diagnosis of prostate cancer

Numerator Instructions: A higher score indicates appropriate treatment of patients with prostate cancer at low (or very low) risk of recurrence.

Numerator Options:
Performance Met: Bone scan not performed prior to initiation of treatment nor at any time since diagnosis of prostate cancer (3270F)
OR
Denominator Exception: Documentation of medical reason(s) for performing a bone scan (including documented pain, salvage therapy, other medical reasons) (3269F with 1P)
OR
Denominator Exception: Documentation of system reason(s) for performing a bone scan (including bone scan ordered by someone other than the reporting physician) (3269F with 3P)
OR
Performance Not Met: Bone scan performed prior to initiation of treatment or at any time since diagnosis of prostate cancer (3269F)

RATIONALE:
A bone scan is generally not required for staging prostate cancer in men with a low (or very low) risk of recurrence and receiving primary therapy. This measure is written as a negative measure so that the performance goal is 100%, consistent with the other measures for this condition.

CLINICAL RECOMMENDATION STATEMENTS:
Routine use of a bone scan is not required for staging asymptomatic men with clinically localized prostate cancer when their PSA level is equal to or less than 20.0 ng/mL. (AUA, 2013)

For symptomatic patients and/or those with a life expectancy of greater than 5 years, a bone scan is appropriate for patients with any of the following: 1) T1 disease with PSA over 20 ng/mL or T2 disease with PSA over 10 ng/mL; 2) a Gleason score of 8 or higher; 3) T3 to T4 tumors; or 4) symptomatic disease. (NCCN, 2015) (Category 2A)

COPYRIGHT:
The Measures are not clinical guidelines, do not establish a standard of medical care, and have not been tested for all potential applications.

The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, eg, use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain.
Commercial uses of the Measures require a license agreement between the user and the PCPI® Foundation (PCPI®) or the American Medical Association (AMA). Neither the American Medical Association (AMA), nor the AMA-convened Physician Consortium for Performance Improvement® (AMA-PCPI), now known as the PCPI, nor their members shall be responsible for any use of the Measures.

AMA and PCPI encourage use of the Measures by other health care professionals, where appropriate.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.

© 2015 PCPI® Foundation and American Medical Association. All Rights Reserved.

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the PCPI and its members and former members of the AMA-PCPI disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

CPT® contained in the Measure specifications is copyright 2004-2016 American Medical Association. LOINC® is copyright 2004-2016 Regenstrief Institute, Inc. This material contains SNOMED CLINICAL TERMS (SNOMED CT®) copyright 2004-2016 International Health Terminology Standards Development Organisation (IHTSDO). ICD-10 is copyright 2016 World Health Organization. All Rights Reserved.
2017 Registry Individual Measure Flow

#102 NQF #0389: Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients

**Sample Calculations:**

Data Completeness:

\[ \text{Data Completeness} = \frac{\text{Performance Met \((n=4\) episodes)} + \text{Denominator Exception \((b^1+b^2=1\) episode)} + \text{Performance Not Met \((c=2\) episodes)} = 7 \text{ episodes} = 87.50\%}{\text{Eligible Population / Denominator \((d=6\) episodes)} = 8 \text{ episodes}} \]

Performance Rate:

\[ \text{Performance Rate} = \frac{\text{Performance Met \((n=4\) episodes)} = 4 \text{ episodes} = 66.67\%}{\text{Data Completeness Numerator \((7\) episodes) - Denominator Exception \((b^1+b^2=1\) episode)} = 6 \text{ episodes}} \]

*See the posted Measure Specification for specific coding and instructions to report this measure.

NOTE: Reporting Frequency: Episode
2017 Registry Individual Measure Flow

#102 NQF #0389: Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients

Please refer to the specific section of the Measure Specification to identify the denominator and numerator information for use in reporting this Individual Measure.

1. Start with Denominator

2. Check Patients Gender:
   a. If Male Gender equals No, do not include in Eligible Patient Population. Stop Processing.
   b. If Male Gender equals Yes, proceed to check Patient Diagnosis.

3. Check Patient Diagnosis:
   a. If Diagnosis of Prostate Cancer as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing.
   b. If Diagnosis of Prostate Cancer as Listed in the Denominator equals Yes, proceed to check Encounter Performed.

4. Check Encounter Performed:
   a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing.
   b. If Encounter as Listed in the Denominator equals Yes, proceed to check Low (or Very Low) Risk of Recurrence, Prostate Cancer Performed.

5. Check Low (or Very Low) Risk of Recurrence, Prostate Cancer Performed:
   a. If Low (or Very Low) Risk of Recurrence, Prostate Cancer as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing.
   b. If Low (or Very Low) Risk of Recurrence, Prostate Cancer as Listed in the Denominator equals Yes, include in the Eligible population.

6. Denominator Population:
   a. Denominator population is all Eligible Patients in the denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 8 episodes in the sample calculation.

7. Start Numerator

8. Check Bone Scan Not Performed Prior to Initiation of Treatment Nor at any Time Since Diagnosis of Prostate Cancer:
   a. If Bone Scan Not Performed Prior to Initiation of Treatment Nor at any Time Since Diagnosis of Prostate Cancer equals Yes, include in Data Completeness Met and Performance Met.
b. Data Completeness Met and Performance Met letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 4 episodes in Sample Calculation.

c. If Bone Scan Not Performed Prior to Initiation of Treatment Nor at any Time Since Diagnosis of Prostate Cancer equals No, proceed to Documentation of Medical Reason(s) for Performing a Bone Scan.

9. Check Documentation of Medical Reason(s) for Performing a Bone Scan:
   a. If Documentation of Medical Reason(s) for Performing a Bone Scan equals Yes, include in Data Completeness Met and Denominator Exception.
   b. Data Completeness Met and Denominator Exception letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter b1 equals 1 episode in the Sample Calculation.
   c. If Documentation of Medical Reason(s) for Performing a Bone Scan equals No, proceed to Documentation of System Reason(s) for Performing a Bone Scan.

10. Check Documentation of System Reason(s) for Performing a Bone Scan:
    a. If Documentation of System Reason(s) for Performing a Bone Scan equals Yes, include in the Data Completeness Met and Denominator Exception.
    b. Data Completeness Met and Denominator Exception letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter b2 equals 0 episodes in the Sample Calculation.
    c. If Documentation of System Reason(s) for Performing a Bone Scan equals No, proceed to Bone Scan Performed Prior to Initiation of Treatment or at any Time Since Diagnosis of Prostate Cancer.

11. Check Bone Scan Performed Prior to Initiation of Treatment or at any Time Since Diagnosis of Prostate Cancer:
    a. If Bone Scan Performed Prior to Initiation of Treatment or at any Time Since Diagnosis of Prostate Cancer equals Yes, include in the Data Completeness Met and Performance Not Met.
    b. Data Completeness Met and Performance Not Met letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter c equals 2 episodes in the Sample Calculation.
    c. If Bone Scan Performed Prior to Initiation of Treatment or at any Time Since Diagnosis of Prostate Cancer equals No, proceed to Data Completeness Not Met.

12. Check Data Completeness Not Met:
    a. If Data Completeness Not Met equals No, Quality Data Code or equivalent not reported. 1 episode has been subtracted from the data completeness in the sample calculation.

**SAMPLE CALCULATIONS:**

<table>
<thead>
<tr>
<th>Data Completeness =</th>
<th>Performance Met (a=4 episodes) + Denominator Exception (b^1+b^2=1 episode) + Performance Not Met (c=2 episodes) = 7 episodes = 87.53%</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Eligible Population / Denominator (c=8 episodes) = 8 episodes</td>
</tr>
</tbody>
</table>
| Performance Rate =  | Performance Met (a=4 episodes) = 4 episodes = 66.67% \[
|                     | Data Completeness Numerator (7 episodes) - Denominator Exception (b^1+b^2=1 episode) = 6 episodes                               |

Version 1.0  
11/15/2016  

CPT only copyright 2016 American Medical Association. All rights reserved.